A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
A study for adult patients with recurrent glioblastoma multiforme using study drug SL-701
Sponsor: Stemline Therapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAN8010
U.S. Govt. ID: NCT02078648
Contact: Fabio Iwamoto: 212-342-0571 / fi2146@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if SL-701 is safe and tolerable for patients with recurrent glioblastoma multiforme (GBM). The study will also look at what effect SL-701 has on patient's brain tumor. SL-701 is a type of anti-cancer vaccine made up of parts 3 different short proteins called "peptides" which are frequently found on this type of brain tumor. The vaccine is intended to activate the immune system to recognize and kill the brain tumor cells that have the same protein.
This study is closed
Investigator
Fabio Iwamoto, MD
Do You Qualify?
Do you have a confirmed diagnosis of GBM? Yes No
Have you had prior cancer chemotherapy or an investigational agent for recurrent/progressive GBM as part of initial therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Fabio Iwamoto
fi2146@cumc.columbia.edu
212-342-0571
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE